Breast Cancer Clinical Trial
Official title:
A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole +/- goserelin (the latter for pre-menopausal women only) may fight breast cancer
by lowering the amount of estrogen the body makes. OSI-906 and erlotinib hydrochloride may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is
not yet known whether hormone therapy and OSI-906 are more effective when given with or
without erlotinib hydrochloride in treating hormone-sensitive metastatic breast cancer.
PURPOSE: This phase II trial is studying how well giving hormone therapy together with
OSI-906 with or without erlotinib hydrochloride works in treating hormone-sensitive patients
with metastatic breast cancer.
OBJECTIVES:
Primary
- To determine the antitumor activity of letrozole +/- goserelin (the latter for
pre-menopausal women only) in combination with IGF-1R inhibitor OSI-906 with or without
erlotinib hydrochloride, measured by time to progression, in patients with
hormone-sensitive metastatic breast cancer.
Secondary
- To determine the safety of these regimens in these patients.
- To determine the response rate in patients treated with these regimens.
- To measure circulating C-peptide, IGF-1, and IGFBP-3 levels in patients treated with
these regimens.
- To correlate the expression of IGF-IR, EGFR, HER2, Y1316 and Y1131 pIGF-1R, PTEN, S473
pAkt, pMAPK, S118 (MAPK site), and S167 (Akt and S6 site) pER in formalin-fixed
paraffin blocks (FFPB) with clinical outcome and luminal A vs. luminal B subtypes of
breast cancer.
- To correlate the mutational status of PI3K (E542K, E545K, H1047R) in DNA extracted from
FFPB or fresh biopsy with clinical outcome and luminal A vs. luminal B subtypes of
breast cancer
OUTLINE: This is a multicenter study. Stratification will be based on previous exposure to
endocrine therapy: (Arm I) no previous endocrine therapy or have completed adjuvant therapy
> 6 months prior to study enrollment; (Arm II) patients that had previous endocrine therapy
in the metastatic setting or had metastatic recurrence within 6 months of adjuvant endocrine
therapy.
- Arm I: Patients receive oral letrozole once daily on days 1-28 +/- subcutaneous
goserelin* on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28.
Treatment repeats every 28 days in the absence of disease progression or unacceptable
toxicity.
- Arm II: Patients receive oral letrozole +/- subcutaneous goserelin* and IGF-1R
inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once
daily on days 1-28. Treatment repeats every 28 days in the absence of disease
progression or unacceptable toxicity.
NOTE: *Goserelin will only be given to premenopausal patients.
Tumor tissue samples from original diagnosis or from fresh biopsy tissue are collected for
biomarker analysis and other studies.
After completion of study therapy, patients are followed periodically.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |